FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for HER2-mutant non-small cell lung cancer

FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for HER2-mutant non-small cell lung cancer

http://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-acceler...

Source: FDA Center for Drug Evaluation and Research - What's New - August 11, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news

More News: Cancer | Cancer & Oncology | Drugs & Pharmacology | Grants | HER2 | Herceptin | Lung Cancer | Non-Small Cell Lung Cancer